Zacks.com showed highlights Stoneco, Centene, CVS Health and Pfizer

Chicago, IL – May 14, 2025 – The shares in the article this week are Stoneco Ltd. Stne, Centene Corp. CNC, CVS Health Corp. CVS and Pfizer Inc. Pfe.

The Wall Street recorded a strong rally on Monday, which was driven by another optimism over the US China trade relationships. A 90-day agreement between the two nations to reduce tariffs has resumed hope of facilitating global trade voltages. The United States will reduce the duties for Chinese imports from steeply 145% to 30%, while China has agreed to reduce its retaliation tariffs for American goods from 125% to 10%, which signals a shift from confrontation to cooperation.

The markets reacted positively, with the S&P 500 jumping by 3.3% to settle at 5,844.19, while the NASDAQ composite achieved a greater performance and increased by 4.4% and at 18,708.34 conclusion. The Dow Jones Industrial Average reached 2.8% and landed at 42,410.10.

If the markets are backed up and improves the mood, this can now be a cheap moment to shift the focus on value stakes. Cool feared as a commercial supply, companies with strong foundations could exceed but beaten prices.

When evaluating value tactics, one of the most effective evaluation metrics is the price of price to cash flow (p/cf). Like companies Stoneco Ltd.Present Centene Corp.Present CVS Health Corp. And Pfizer Inc. Due to a low P/CF ratio. The P/CF ratio evaluates the market price of a share compared to the cash flow amount that the company Pro Sharing-Base generates-the number is lower, the better.

Value Investing is considered one of the best practices when it comes to choosing stocks. It is essentially about selecting shares that arrive fundamentally, but have been depressed by some external factors. Such stocks are ready to recognize the inherent value of companies as and when investors. The value investment strategy certainly fits best for investors with a long -term horizon.

There are various evaluation metrics to determine the inherent strength of a stock. A random selection of a relationship cannot meet your purpose if you want a realistic assessment of the financial position of a company. For this, the price for the cash flow (or the P/CF) ratio is one of the most important metrics.

The price-cash flow metric evaluates the market price of a share compared to the cash flow amount that the company Pro Sharing-Base generates-the number is lower, the better. One of the important factors that make P/CF a very reliable metric is that the operational cash flow does not attribute not to payment -related fees such as depreciation and amortization to the net result and really diagnosed a company's financial health.

Analysts warn that the result of a company is subject to the estimates of the accounting and manipulation of management. However, the cash flow is reliable. Net Cashflow reveals how much money a company actually generates and how effective management provides the same.

A positive cash flow indicates an increase in the liquid assets of a company. The company gives the company the means to pay debts, to fulfill its expenses, to re -invest in his business, to endure swings and finally repay its shareholders. The negative cash flow implies a decline in the liquidity of the company, which in turn lowers its flexibility to support these movements.

An investment decision based exclusively on the P/CF metric cannot provide the desired results. In order to identify shares that are traded with a discount, you should expand your search criteria and also take into account the ratio of price-to-book ratio, price-performance ratio and price-to-sale ratio. Adding a cheap Zack rank and a added value from A or B to your search criteria should lead to even better results, since these eliminate the likelihood of falling into a value trap.

Here are the parameters for the selection of the inventory for real value:

Here are four of the 16 valuables that have qualified the screening:

StoneA leading provider of financial technology and software solutions bears a Zacks rank 1. On average, the company has a surprise with four quarters of 6.4%of 6.4%. Here you will find the full list of today's Zacks #1 rank shares.

The Zacks Consensus estimate for Stone's last financial year sales and profit per share (EPS) proposes growth of 9.8% and 2.2% compared to the same period last year. Stne has a added value of B. Shares from Stne last year by 12.3%.

CenterA leading healthcare company, bears a Zacks rank No. 2. On average, the company has a surprise with four quarters of 25.5%of 25.5%. (Look at the Zacks profit calendar to be ahead of market sensitive messages.)

The Zacks Consensus estimate for ongoing sales and the EPS of Centene in the financial year implies a growth of 10.3% and 1.4% compared to the same period in the previous year. Centene has dropped by 18.2% of the Centene A. shares in Centene.

CVS healthA leading company for health solutions bears a Zacks rank #2. The company has an average surprise with four quarters of 18.1%of 18.1%.

The Zack's consensus estimate for ongoing sales and the EPS of CVS Health indicate growth of 3.6% and 11.8% compared to the same period in the previous year. CVS Health has increased a value added by AA shares of CVS by 15.7% last year.

Pfizerthat develops, manufactures, markets, distributes, distributes and sells biopharmaceutical products, wears a Zacks rank #2. The company has an average surprise with four quarters of 43.5%of 43.5%.

The Zacks Consensus estimate for ongoing sales and EPS of Pfizer suggests a decline of 0.7% or 1% compared to the same period last year. Pfizer has decreased by 18.6% of AA shares from PFEs last year.

You can put the rest of the shares on this list on this list by now registering for your 2-week free trial version with the research assistant and using this screen in your own trade. In addition, you can create your own strategies and examine it first before daring the investment boost.

The research assistant is a great place to start. It's easy to use. Everything is in simple language. And it is very intuitive. Still your research assistant attempt today. The next time you read an economic report, open the research assistant, connect your finds and see which gemstones come out.

Click here to register for a free test version at the research assistant today.

Disclosure: Officials, directors and employees of Zacks Investment Research can own or sell short securities and/or have long and/or short positions in options that are mentioned. A connected investment advisory company can have short securities and/or in this material in options that have been mentioned in this material, have long and/or short positions.

Disclosure: Performance information for the portfolios and strategies of Zacks can be found at:

Since 2000, our top bearing strategies have flipped up with the average profit of S&P +7.7% per year. Surprisingly, they rose with average profit from +48.4%, +50.2% And +56.7% per year.

Today you can access your live picks without any costs or obligation.

See shares for free >>

For the rest of this screen of the week, please visit Zacks.com at:

Follow us on Twitter:

Accompany us on Facebook:

Together with connected companies (including a broker dealer and an investment consultant), Zack's Investment Research is subject to transactions with the above securities for customers of such partners.

Contact: Jim Giaquinto

Company: zacks.com

Telephone: 312-265-9268

E -mail: pr@zacks.com

Visit:

Zacks.com offers investment resources and informs you about these resources that you may use for your own investment decisions. Zacks will provide you with information about this resource that is subject to the Zacks “Terms of Use” for the “Use of Liability”. www.zacks.com/disclaimer.

The performance in the past is not a guarantee of future results. In an investment inherent, the potential for losses is. This material is only provided for information purposes, and nothing is investments, legal, accounting or tax advice or a recommendation to buy, sell or maintain security. There is no recommendation or advice whether an investment is suitable for a specific investor. It should not be assumed that investments in securities, companies, sectors or markets that have been identified and described were or become profitable. All information is current at the time of the current date and can be changed without prior notice. All expressed views or opinions may not reflect that of the entire company. Zack's Investment Research does not participate in investment banking, market manufacturing or asset management activities of securities. These returns come from hypothetical portfolios, which consist of shares with Zacks rank = 1, which were reproduced monthly with zero transaction costs. These are not the returns of the actual stock portfolios. The S&P 500 is a non -managed index. Visit information about the performance numbers displayed in this press release.

Would you like the latest recommendations from Zack's Investment Research? Today you can download 7 best stocks for the next 30 days. Click here to receive this free report

Pfizer Inc. (PFE): Report on free stock analysis

CVS Health Corporation (CVS): Free stock analysis report

Centene Corporation (CNC): Report on free stock analysis

Stoneco Ltd. (Stne): Free stock analysis report

This article was originally published in Zack's Investment Research (Zacks.com).

Zacks Investment Research